A Phase I, Single-Center, Open-Label, 3-Way Crossover, Randomized Single Dose Study to Evaluate the Food Effect on the Pharmacokinetics of TT-00420 Tablet and to Determine the Relative Bioavailability of TT-00420 Tablet Versus TT-00420 Capsule in Adult Healthy Volunteers
Overview
- Phase
- Phase 1
- Intervention
- TT-00420 Capsule
- Conditions
- Healthy
- Sponsor
- TransThera Sciences (Nanjing), Inc.
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Area under the curve (AUC0-∞) of TT-00420
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This study is an open-label, 3-way crossover randomized study in adult healthy volunteers to evaluate the relative bioavailability of TT-00420 tablet and capsule formulations and to evaluate food effect on the pharmacokinetics of TT-00420 tablet.
Detailed Description
Subjects will be randomized to one of three treatment sequences. Each sequence will contain up to 8 subjects. In each treatment sequence, subjects undergo a baseline/screening period, three treatment periods, and a follow-up visit. Subjects will be administered a single dose of TT-00420 on Day 1 of either TT-00420 tablet under fed condition, TT-00420 tablet under fasting condition, or capsule under fasting condition and crossed over after at least a 14-day washout period.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female subjects between 18 and 64 years of age inclusive, at the time of signing the informed consent.
- •Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and weighs at least 50 kg.
- •Healthy as determined by the investigator based on medical history, clinical laboratory results (serum chemistry, hematology, urinalysis, and serology), vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only, if per the investigator discretion, the investigator judges and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Male subjects must not donate sperm starting at Screening, throughout the study period and for at least 90 days after final study drug administration.
- •Male subjects with female sexual partner(s) of reproductive potential may be enrolled if the male:
- •is documented to be surgically sterile (i.e., successfully vasectomized), or
- •agrees to use 2 methods of highly effective contraception and agree to refrain from sperm donation from the time of Screening through 90 days post-doseHighly effective includes male condom with spermicide PLUS an effective contraceptive for the female partner that includes: OCPs, long-acting implantable hormones, injectable hormones, a vaginal ring or IUD
- •If female, is of non-childbearing potential, meeting the following requirements:
- •pre-menopausal with documentation of surgical sterilization (i.e., hysterectomy, bilateral tubal ligation, bilateral oophorectomy, or bilateral salpingectomy at least 3 months prior to study entry), or
- •post-menopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and with follicle-stimulating hormone (FSH) level ≥ 40 mIU/mL at Screening
Exclusion Criteria
- •Any history of clinically serious disease.
- •Any active or unstable clinically significant medical condition as judged by the Investigator.
- •History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- •Hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes.
- •Hypersensitivity or allergy for components of the prescribed meal
- •Received any investigational drug within 30 days or 5 half-lives(whichever is longer, if known) before the study.
- •Subject who has undergone major surgery ≤ 2 months before study drug administration.
- •Impaired cardiac function including clinically significant arrhythmias or clinically significant abnormality in clinical test, including but not limited to any of the following at Screening and Admission, repeat testing is allowed for verification, at the discretion of the Investigator:
- •Heart rate \< 45 beats per minute (bpm) or \> 90 bpm.
- •Systolic blood pressure (SBP) \< 90 mmHg or \> 140 mmHg; diastolic blood pressure (DBP) \< 50 mmHg or \> 90 mmHg.
Arms & Interventions
Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]
Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
Intervention: TT-00420 Capsule
Sequence 1 [TT-00420 tablet, fed; TT-00420 tablet, fasted; TT-00420 capsule, fasted]
Participants will receive a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions. There will be at least a 14-day wash-out period between each dose.
Intervention: TT-00420 Tablet
Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]
Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.
Intervention: TT-00420 Capsule
Sequence 2 [TT-00420 tablet, fasted; TT-00420 capsule, fed; TT-00420 tablet, fed]
Participants will receive a single dose of TT-00420 tablet under fasted conditions, followed by a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions. There will be at least a 14-day wash-out period between each dose.
Intervention: TT-00420 Tablet
Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]
Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.
Intervention: TT-00420 Capsule
Sequence 3 [TT-00420 capsule, fasted; TT-00420 tablet, fed; TT-00420 tablet, fasted]
Participants will receive a single dose of TT-00420 capsule under fasted conditions, followed by a single dose of TT-00420 tablet under fed conditions, followed by a single dose of TT-00420 tablet under fasted conditions. There will be at least a 14-day wash-out period between each dose.
Intervention: TT-00420 Tablet
Outcomes
Primary Outcomes
Area under the curve (AUC0-∞) of TT-00420
Time Frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)
Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.
Area under the curve (AUC0-t) of TT-00420
Time Frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)
Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.
Maximum observed concentration (Cmax) of TT-00420
Time Frame: From pre-dose up to 240 hours post-dose each period (each period is 14 days)
Blood samples will be collected at indicated time points for pharmacokinetic analysis of TT-00420.
Secondary Outcomes
- Incidence of abnormal clinical laboratory tests(At baseline and from admission to discharge, up to 12 days per period (each period is 14 days))
- Incidence of abnormal physical examinations(At baseline and from admission to discharge, up to 12 days per period (each period is 14 days))
- Incidence of abnormal weight(At baseline and from admission to discharge, up to 12 days per period (each period is 14 days))
- Incidence of abnormal 12-lead electrocardiogram(At baseline and from admission to discharge, up to 12 days per period (each period is 14 days))
- Incidence of abnormal vital signs(At baseline and from admission to discharge, up to 12 days per period (each period is 14 days))
- Half life (t1/2) of TT-00420(From pre-dose up to 240 hours post-dose each period (each period is 14 days))
- Time of maximum concentration (tmax) of TT-00420(From pre-dose up to 240 hours post-dose each period (each period is 14 days))
- Volume of distribution (Vd/F) of TT-00420(From pre-dose up to 240 hours post-dose each period (each period is 14 days))
- Number of participants with adverse events (AEs)(From admission up to 10 days following discharge)
- Clearance (CL/F) of TT-00420(From pre-dose up to 240 hours post-dose each period (each period is 14 days))